N
Nicole S Engen
Researcher at University of Minnesota
Publications - 3
Citations - 469
Nicole S Engen is an academic researcher from University of Minnesota. The author has contributed to research in topics: Placebo & Hydroxychloroquine. The author has an hindex of 3, co-authored 3 publications receiving 322 citations.
Papers
More filters
Journal ArticleDOI
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.
Caleb P Skipper,Katelyn A Pastick,Nicole S Engen,Ananta S Bangdiwala,Mahsa Abassi,Sarah M Lofgren,Darlisha A. Williams,Elizabeth C Okafor,Matthew F Pullen,Melanie R. Nicol,Alanna A Nascene,Katherine Huppler Hullsiek,Matthew P. Cheng,Darlette Luke,Sylvain A. Lother,Lauren J. MacKenzie,Glen Drobot,Lauren E. Kelly,Ilan S. Schwartz,Ryan Zarychanski,Emily G. McDonald,Todd C. Lee,Radha Rajasingham,David R. Boulware +23 more
TL;DR: This randomized, double-blind, placebo-controlled trial evaluated effects of oral hydroxychloroquine on symptoms and disease severity in adult outpatients with early COVID-19.
Journal ArticleDOI
Symptoms of COVID-19 Outpatients in the United States
Matthew F Pullen,Caleb P Skipper,Katherine Huppler Hullsiek,Ananta S Bangdiwala,Katelyn A Pastick,Elizabeth C Okafor,Sarah M Lofgren,Radha Rajasingham,Nicole S Engen,Alison Galdys,Darlisha A. Williams,Mahsa Abassi,David R. Boulware +12 more
TL;DR: Symptomatic persons with probable Sars-CoV-2 infection present similarly to those with confirmed SARS- CoV- 2 infection, and there was no pattern of symptom frequency over time.
Journal ArticleDOI
Investigating the Efficacy of Clinical Trial Monitoring Strategies Design and Implementation of the Cluster Randomized START Monitoring Substudy
Katherine Huppler Hullsiek,Jonathan M. Kagan,Nicole S Engen,Jesper Grarup,Fleur Hudson,Eileen Denning,Catherine L. Carey,David Courtney-Rodgers,Elizabeth Finley,Per O. Jansson,Mary T. Pearson,Dwight E. Peavy,Waldo H. Belloso +12 more
TL;DR: This study will determine if on-site monitoring increases the identification of major protocol deviations (eligibility or consent violations, improper study drug use, primary or serious event underreporting, data alteration or fraud).